Related Experiment Video
Updated: Jun 20, 2025
07:25
Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
3.0K
Clinical Outcomes Following SARS-CoV-2 Infection in Pediatric Cystic Fibrosis Patients
Andy P Huang1, Andrea Espina Rey2, Christie G Cherian3
1Medicine, University of Central Florida College of Medicine, Orlando, USA.
Cureus
|July 22, 2024
Summary
Pediatric cystic fibrosis (CF) patients with COVID-19 experienced similar outcomes to controls, with fewer pulmonary exacerbations. This suggests COVID-19 infection does not significantly worsen lung function in these children.
Area of Science:
- Pulmonology
- Infectious Diseases
- Genetics
Background:
- Cystic fibrosis (CF) is a genetic disorder affecting the CFTR chloride channel, leading to mucus buildup and lung function decline.
- The impact of COVID-19 on pediatric CF patients remains understudied, despite concerns about increased complication risks.
- This study investigates the relationship between CF and COVID-19 in children.
Purpose of the Study:
- To compare adverse outcomes in pediatric CF patients with COVID-19 against control groups.
- To assess the impact of COVID-19 on lung function (FEV1%pred) in pediatric CF patients.
- To identify factors influencing COVID-19 outcomes in CF.
Main Methods:
- Retrospective review of pediatric CF patients with COVID-19 (N=69) from March 2020 to March 2023.
- Comparison with two equally sized control cohorts: CF-only and COVID-19-only patients.
- Assessment of adverse outcomes and lung function (FEV1%pred); statistical analysis using Fisher's exact test and t-testing.
Main Results:
- Pediatric CF patients with COVID-19 showed similar adverse outcomes compared to control groups.
- No significant deterioration in lung function (FEV1%pred) was observed in CF/COVID patients.
- CF/COVID patients experienced significantly fewer pulmonary exacerbations than CF-only patients (p=0.004).
Conclusions:
- Pediatric CF patients generally tolerate COVID-19 infection well, with outcomes comparable to non-CF peers.
- COVID-19 infection did not lead to significant pulmonary function decline in pediatric CF patients.
- Reduced pulmonary exacerbations in CF/COVID patients may be linked to increased monitoring and care adherence.
Related Concept Videos
01:24Cystic Fibrosis: Management
154
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
154
01:23Cystic Fibrosis: Pathogenesis
202
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
202
01:29Pneumonia II: Pathophysiology
240
The pathophysiology of pneumonia involves the following steps:
240
01:29Acute Respiratory Failure-V
127
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
127
01:17Pulmonary Cycle: Exhalation
1.5K
In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.5K